Form: 8-K

Current report filing

February 24, 2022



intro.jpg




Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward-looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Commission (the “SEC”), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q.

Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.



ameh.jpg
www.apollomed.net
2



Company Overview

Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner.

companyoverview.jpg
ameh.jpg
www.apollomed.net
3



Q4/Year-End and Recent Highlights

                                
strongfinancialresultsa.jpg
strengthenleadership.jpg
strategictransactionsa.jpg
Strong YE 2021 financial results Strengthening
leadership team
Strategic transactions
EPS (diluted)
$1.63
arrowup.jpg 61% from $1.01
New board appointments:

Weili Dai and J. Lorraine Estradas, R.N., B.S.N., M.P.H.


Appointed Allen Hsu as Chief Growth Officer


Added resources to boost operations and business development efforts
Closed the following transaction in Q1 2022:

Orma Health
Revenue
$773.9M
arrowup.jpg 13% from $687.2M
Signed agreement to acquire 100% of Jade Health Medical Group, an SF Bay Area-based primary and specialty care physicians’ group
Net income attr. to AMEH
$73.9M
arrowup.jpg 95% from $37.9M
Adj.
EBITDA*
$174.2M
arrowup.jpg 34% from $129.9M
*See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information.


ameh.jpg
www.apollomed.net
4



Historical Financial Profile


historicalfinancialprofilea.jpg
ameh.jpg
www.apollomed.net
5



Summary of Selected Financial Results

Three Months Ended December 31, Twelve Months Ended December 31,
$ in 000s except per share data 2021 2020 2021 2020
Revenue
Capitation, net $ 154,874  $ 140,923  $ 593,224  $ 557,326 
Risk pool settlements and incentives 17,481  23,212  111,627  77,367 
Management fee income 9,614  8,638  35,959  34,850 
Fee-for-service, net 11,596  3,249  26,564  12,683 
Other income 1,535  760  6,541  4,954 
Total revenue 195,100  176,782  773,915  687,180 
Total expenses 192,852  150,907  675,736  606,677 
Income from operations 2,248 25,875 98,179 80,503
Net (loss) income (19,309) 12,908  49,294  122,320 
Net (loss) income attributable to noncontrolling interests (33,079) 2,851  (24,564) 84,454 
Net income attributable to ApolloMed $ 13,770 $ 10,057 $ 73,858 $ 37,866
Earnings per share - diluted $ 0.30 $ 0.27 $ 1.63 $ 1.01




ameh.jpg
www.apollomed.net
6



Revenue Breakdown

revenuebreakdowna.jpg
ameh.jpg
www.apollomed.net
7



Business Mix by Payer Type

FULL YEAR 2021
(% OF TOTAL REVENUE)
chart-57ab3c0a95ba403d876a.jpg



ameh.jpg
www.apollomed.net
8



Balance Sheet Highlights

$ in millions 12/31/2021 12/31/2020 $ Change % Change
Cash and cash equivalents and investments in marketable securities $286.5 $261.2 $25.3
arrowup2.jpg
10%
Working capital $283.4 $223.6 $59.8
arrowup2.jpg
27%
Total stockholders’ equity $460.5 $330.9 $129.6
arrowup2.jpg
39%




ameh.jpg
www.apollomed.net
9



Current Capitalization

(figures in millions, except per share price)
Recent Share Price (as of 2/18/2022) $ 54.37
Common Shares Outstanding 56.0
Market Capitalization $ 3,044.7
Plus: Total Bank Debt 188.0
Less: Cash and Cash Equivalents (1)
(170.3)
Implied Enterprise Value $ 3,062.4
Notes: Letters of Credit Availability on Revolving Credit Facility $ 25.0

Note: Data is as of 12/31/2021 unless otherwise stated.
(1) Excludes restricted cash of $62.8M.



ameh.jpg
www.apollomed.net
10



2022 Guidance

$ in millions Actual YE 2021
Results
 2022 Guidance Range % Growth
Total Revenue $773.9 $1,030.0 - $1,080.0
33% - 40%










ameh.jpg
www.apollomed.net
11



Reconciliation of Net Income to EBITDA and Adjusted EBITDA

Year Ended December 31,
($ in millions) 2021 2020
Net (loss) income $ 49.3  $ 122.3 
Interest expense 5.4  9.5 
Interest income (1.6) (2.8)
(Benefit from) provision for income taxes 28.5  56.1 
Depreciation and amortization 17.5  18.4 
EBITDA(1)
$ 99.1  $ 203.5 
Loss (income) from equity method investments $ 4.3  $ (3.7)
Other expense (income) 11.2  (1.1)
Unrealized loss on investments 12.1  — 
Gain on sale of equity method investment —  (99.8)
Provider bonus payments 7.2  6.5 
Stock-based compensation 6.7  3.4 
APC excluded assets costs 10.3  2.0 
Net loss adjustment for recently acquired IPAs 23.1  19.2 
Adjusted EBITDA(1)
$ 174.2  $ 129.9 

(1) See “Use of Non-GAAP Financial Measures” slide for more information.


ameh.jpg
www.apollomed.net
12



Use of Non-GAAP Financial Measures


This presentation contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision for doubtful accounts and other income earned that are not related to the Company's normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired.

ApolloMed believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.





ameh.jpg
www.apollomed.net
13




Key Acronyms

ACO: Accountable Care Organization
AIPBP: All-Inclusive Population-Based Payments
CMMI: Center for Medicare and Medicaid Innovation
CMS: Centers for Medicare & Medicaid Services
DME: Durable Medical Equipment
Health Plan/Payors: Health Insurance Companies
HMO: Health Maintenance Organization
IPA: Independent Practice Association
NCI: Non-Controlling Interest







NMM: Network Medical Management, Inc.
MSA: Master Service Agreement
MSO: Management Services Organization
NGACO: Next Generation Accountable Care Organization
PCP: Primary Care Physician
PMPM: Per Member Per Month
SNF: Skilled Nursing Facility
VIE: Variable Interest Entity







ameh.jpg
www.apollomed.net
14



ending.jpg